Li Bingyan, Tan Wei, Wang Zicong, Zhou Haixiang, Zou Jingling, Li Yun, Yoshida Shigeo, Zhou Yedi
Department of Ophthalmology, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
Hunan Clinical Research Center of Ophthalmic Disease, Changsha, Hunan, 410011, China.
Heliyon. 2023 Jul 14;9(7):e18228. doi: 10.1016/j.heliyon.2023.e18228. eCollection 2023 Jul.
Gene therapy is a treatment approach at the genetic level, which brings great advances in many diseases and develops rapidly in recent years. Currently, its mechanism of action is mainly through the replacement of missing or defective genes, or the reduction of harmful gene products. However, the application of gene therapy in ophthalmology remains limited.
A total of 1143 articles and reviews published in the field of ocular gene therapies were found in the Web of Science Core Collection database and used for the bibliometric analysis. CiteSpace was mainly applied to the network analysis of countries, institutions, keywords, and dual-map overlay of journals. The visual analysis of authors, journals, and references was used by VOSviewer. The geographical distribution of publications was conducted by R language.
The annual publications are increasing in general. Currently, the USA and the UK are two main sources of publications in this field. Switzerland, Denmark, and Finland are the top 3 countries that establish the most cooperation and exchanges with other countries or regions. The most cited and co-cited journal in this field is . Gene therapy studies for eye diseases are mainly focused on retinal dysfunctions by the analysis of references, keywords, and counting of original research, including Leber's congenital amaurosis and retinitis pigmentosa.
This study used bibliometrics to analyze overall characteristics and put forward prospects for the future in the field of gene therapy in ophthalmology. Ocular diseases, especially hereditary retinal diseases, will be the major focus of gene therapy in the future.
基因治疗是一种基因水平的治疗方法,在许多疾病的治疗方面取得了巨大进展,近年来发展迅速。目前,其作用机制主要是通过替换缺失或有缺陷的基因,或减少有害基因产物。然而,基因治疗在眼科的应用仍然有限。
在科学网核心合集数据库中检索到1143篇发表于眼部基因治疗领域的文章和综述,并用于文献计量分析。CiteSpace主要应用于国家、机构、关键词的网络分析以及期刊的双图叠加分析。VOSviewer用于作者、期刊和参考文献的可视化分析。出版物的地理分布通过R语言进行。
总体上年度出版物数量在增加。目前,美国和英国是该领域的两个主要出版物来源国。瑞士、丹麦和芬兰是与其他国家或地区建立合作与交流最多的前三个国家。该领域被引频次最高和共被引的期刊是 。通过参考文献、关键词分析以及原始研究计数发现,眼部疾病的基因治疗研究主要集中在视网膜功能障碍,包括莱伯先天性黑蒙和视网膜色素变性。
本研究运用文献计量学方法分析了眼科基因治疗领域的总体特征并提出了未来展望。眼部疾病,尤其是遗传性视网膜疾病,将是未来基因治疗的主要重点。